Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Clinical trial NCT05948943 · RECRUITING
Trial details
- NCT number
- NCT05948943
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-24
- Primary completion
- 2028-05-31
- Enrollment
- 232
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.